<DOC>
	<DOCNO>NCT01303952</DOCNO>
	<brief_summary>Evaluation efficacy safety eculizumab symptomatic transfusion-dependent patient untreated refractory hemolytic cold agglutinin disease ( CAD )</brief_summary>
	<brief_title>Therapy Chronic Cold Agglutinin Disease With Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<mesh_term>Cold agglutinin</mesh_term>
	<mesh_term>Agglutinins</mesh_term>
	<criteria>Individuals least 18 year age Diagnosis CAD define combination chronic hemolysis , cold agglutinin titer ( IgM IgA ) &gt; 64 4°C , positive direct antiglobulin test ( DAT ) perform polyspecific antiserum , negative ( weakly positive ) antiIgG , strongly positive antiC3d LDH level &gt; 2 x upper limit normal ( ULN ) Clinical symptom require treatment , anemia , anemiarelated symptom hemolysisrelated symptom Sufficient supplementation iron , folic acid vitamin B12 prior treatment phase Patient must willing able give write informed consent ; Patients must vaccinate N. meningitidis least 14 day prior treatment Patient must avoid conception trial use method appropriate physical state culture Active aggressive lymphoma require therapy active nonlymphatic malignant disease basal cell carcinoma CIS cervix Liver disease elevate LDH Absolute neutrophil count &lt; 500/µL Presence suspicion active bacterial viral infection , opinion Investigator , treatment start severe recurrent bacterial infection Participation investigational drug trial exposure investigational agent , device , procedure within 30 day prior screen period Pregnant , breastfeeding , intend conceive course study , include Posttreatment Phase History bone marrow/stem cell transplantation Inability cooperate condition , opinion investigator , could increase patient 's risk participate study confound outcome study Hypersensitivity eculizumab , murine proteins one excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cold agglutinin disease</keyword>
	<keyword>hemolysis</keyword>
	<keyword>eculizumab</keyword>
	<keyword>terminal complement inhibition</keyword>
</DOC>